Tag:

Joe Jimenez

Latest Headlines

Latest Headlines

Novartis cost push claims 2,000 jobs in U.S., Switzerland

Novartis ($NVS) has put a number to its job-cutting plans. The Swiss-based drugmaker will shed 2,000 jobs in its home country and the U.S., while shutting down expensive-to-operate European

Novartis chops 2,000 drug development jobs in shift to Asia

With Joe Jimenez at the helm, Novartis ($NVS) has consistently vowed to back its multibillion-dollar R&D empire, avoiding the wholesale restructuring that has upended research operations at many

Want to impress Novartis' CEO? Don't do it in PowerPoint

Novartis ($NVS) CEO Joe Jimenez (photo) tells the New York Times a few things: He's more patient than he used to be. He's learned how to open the door to bad news. And he's not one to compliment a

CEO: Novartis cost cuts to target sales, manufacturing

Fresh off his promises that this year's round of cost-cutting would top last year's $1.9 billion, Novartis ($NVS) CEO Joe Jimenez (photo) gave the Swiss newspaper Handelszeitung some hints about what

Novartis CEO eyes growth strategies for Alcon

Novartis ($NVS) CEO Joe Jimenez (photo) told Reuters in an interview about his plans for the company's new eye-care division Alcon, which include broader use of implanted lenses and a larger presence

Jimenez aims to keep off-patent Diovan in blockbuster territory

Yesterday, we got some hints about Pfizer's post-patent strategy for Lipitor. Novartis ($NVS) CEO Joe Jimenez (photo) is also thinking patents. He's now talking about his company's post-patent plans

Novartis' interest in buying Gen-Probe fizzles, WSJ reports

Novartis' appetite for deals is expected to grow in the near future, but the Swiss drug giant ($NVS) may no longer be interested in gobbling up diagnostic test provider Gen-Probe. After speculation

Novartis Q2 shines on new meds, cost cuts

Novartis ($NVS) kicked off Big Pharma's earnings release with a nice surge in profits. Sales grew by 27% to $14.9 billion, including an 8% increase at the pharma unit. Profits rose by 12%. The strong

Novartis' desire for deals to return soon, CEO says

Novartis ($NVS) could soon be back on the acquisition trail. CEO Joe Jimenez (photo) told Swiss newspaper Aargauer Zeitung that the company's first priority is paying down $22 billion in debt, but

Will Novartis follow through with Gen-Probe bid?

Novartis CEO Joe Jimenez (photo) said last week that one prime dealmaking area for his company might be diagnostics. Along with potential buys in animal health, generics, biotech and consumer health,